Colorado News Desk

Becker Muscular Dystrophy Overview

Becker muscular dystrophy (BMD) is an X-linked recessive disorder due to mutation in the dystrophin gene that results in progressive muscle degeneration and proximal muscle weakness. This condition is less common and less severe than Duchenne muscular dystrophy (DMD). The onset of symptoms is late compared to Duchenne muscular dystrophy, although it varies widely between 5 to 60 years of age. Becker muscular dystrophy (BMD) is caused by specific mutations in the DMD gene.

“Becker Muscular Dystrophy Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Becker Muscular Dystrophy Market. 

The Becker Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Becker Muscular Dystrophy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Becker Muscular Dystrophy treatment therapies with a considerable amount of success over the years. Becker Muscular Dystrophy Key players such as – Epirium Bio, ImmunoForge, Italfarmaco, Santhera Pharmaceuticals, Edgewise Therapeutics, and others, are developing therapies for the Becker Muscular Dystrophy treatment 

• Becker Muscular Dystrophy Emerging therapies such as – EPM-01, PF1801, Givinostat, Vamorolone, EDG 5506, and others are expected to have a significant impact on the Becker Muscular Dystrophy market in the coming years.
• In April 2022, Edgewise Therapeutics initiated a Phase 2 Randomized, Double-blind, Placebo controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy   
• The U.S. Food and Drug Administration (FDA) has granted fast track status to EDG-5506, Edgewise Therapeutics’ investigational oral therapy for Becker muscular dystrophy (BMD) 

Becker Muscular Dystrophy Pipeline Therapeutics Assessment

• Becker Muscular Dystrophy Assessment by Product Type
• Becker Muscular Dystrophy By Stage and Product Type
• Becker Muscular Dystrophy Assessment by Route of Administration
• Becker Muscular Dystrophy By Stage and Route of Administration
• Becker Muscular Dystrophy Assessment by Molecule Type
• Becker Muscular Dystrophy by Stage and Molecule Type 

DelveInsight’s Becker Muscular Dystrophy Report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Becker Muscular Dystrophy Drugs Under Different Phases of Clinical Development Include:

• EPM-01: Epirium Bio
• PF1801: ImmunoForge
• Givinostat: Italfarmaco
• Vamorolone: Santhera Pharmaceuticals
• EDG 5506: Edgewise Therapeutics 

Get a Free Sample PDF Report to know more about Becker Muscular Dystrophy Pipeline Assessment- https://www.delveinsight.com/report-store/becker-muscular-dystrophy-pipeline-insight

Becker Muscular Dystrophy Pipeline Analysis:

The Becker Muscular Dystrophy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Becker Muscular Dystrophy treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Becker Muscular Dystrophy Treatment.
• Becker Muscular Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Becker Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Becker Muscular Dystrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Becker Muscular Dystrophy product details are provided in the report. Download the Becker Muscular Dystrophy pipeline report to learn more about the emerging Becker Muscular Dystrophy therapies

Becker Muscular Dystrophy Pipeline Market Drivers

• Rising incidence of Becker Muscular Dystrophy
• Improving Healthcare Infrastructure
• Demand for New and Effective Drugs

Becker Muscular Dystrophy Pipeline Market Barriers

• Currently no approved drugs for Becker Muscular Dystrophy in any country
• Very few clinical investigational efforts underway for Becker Muscular Dystrophy

Scope of Becker Muscular Dystrophy Pipeline Drug Insight    

• Coverage: Global
• Key Becker Muscular Dystrophy Companies: Epirium Bio, ImmunoForge, Italfarmaco, Santhera Pharmaceuticals, Edgewise Therapeutics, and others
• Key Becker Muscular Dystrophy Therapies: EPM-01, PF1801, Givinostat, Vamorolone, EDG 5506, and others
• Becker Muscular Dystrophy Therapeutic Assessment: Becker Muscular Dystrophy current marketed and Becker Muscular Dystrophy emerging therapies
• Becker Muscular Dystrophy Market Dynamics:  Becker Muscular Dystrophy market drivers and Becker Muscular Dystrophy market barriers 

Request for Sample PDF Report for Becker Muscular Dystrophy Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Becker Muscular Dystrophy drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com